Tags

Type your tag names separated by a space and hit enter

Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease.

Abstract

OBJECTIVE

The polymorphism of the gene encoding methylenetetrahydrofolate reductase (MTHFR) and folic acid nutritional status play important roles in atherosclerosis. The present study investigated the total homocysteine-lowering effect of folic acid in response to the MTHFR genotype in patients who have cardiovascular disease.

METHODS

Twenty-three patients who had cardiovascular disease (ages 44 to 88 y) were supplemented with 5 mg of folic acid/d for 8 wk. Blood samples were collected before and after supplementation for the measurement of folic acid. The presence of the 677C-->T mutation was assessed by polymerase chain reaction followed by restriction enzyme analysis.

RESULTS

After the 8 wk of folic acid supplementation, plasma total homocysteine decreased 40% in patients who had the TT genotype, 23% in those who had the CT genotype, 10% in those who had the CC genotype, and 27% in carriers of the T allele. The plasma total homocysteine-lowering effect of folic acid was significant only in patients who had the CT genotype and in carriers of the T allele.

CONCLUSIONS

The MTHFR polymorphism may be involved in the total homocysteine-lowering effect of folic acid in patients who have cardiovascular disease.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Neurology and Neuroscience, Changhua Christian Hospital, Changhua, Taiwan.

    ,

    Source

    MeSH

    Adult
    Aged
    Aged, 80 and over
    Analysis of Variance
    Cardiovascular Diseases
    Dietary Supplements
    Dose-Response Relationship, Drug
    Female
    Folic Acid
    Genotype
    Homocysteine
    Humans
    Hyperhomocysteinemia
    Male
    Methylenetetrahydrofolate Reductase (NADPH2)
    Middle Aged
    Polymerase Chain Reaction
    Polymorphism, Genetic
    Restriction Mapping
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    15561486

    Citation

    Liu, Chin-San, et al. "Methylenetetrahydrofolate Reductase Polymorphism Determines the Plasma Homocysteine-lowering Effect of Large-dose Folic Acid Supplementation in Patients With Cardiovascular Disease." Nutrition (Burbank, Los Angeles County, Calif.), vol. 20, no. 11-12, 2004, pp. 974-8.
    Liu CS, Chiang HC, Chen HW. Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease. Nutrition. 2004;20(11-12):974-8.
    Liu, C. S., Chiang, H. C., & Chen, H. W. (2004). Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease. Nutrition (Burbank, Los Angeles County, Calif.), 20(11-12), pp. 974-8.
    Liu CS, Chiang HC, Chen HW. Methylenetetrahydrofolate Reductase Polymorphism Determines the Plasma Homocysteine-lowering Effect of Large-dose Folic Acid Supplementation in Patients With Cardiovascular Disease. Nutrition. 2004;20(11-12):974-8. PubMed PMID: 15561486.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease. AU - Liu,Chin-San, AU - Chiang,Hui-Chin, AU - Chen,Haw-Wen, PY - 2003/10/06/received PY - 2004/04/12/accepted PY - 2004/11/25/pubmed PY - 2005/4/9/medline PY - 2004/11/25/entrez SP - 974 EP - 8 JF - Nutrition (Burbank, Los Angeles County, Calif.) JO - Nutrition VL - 20 IS - 11-12 N2 - OBJECTIVE: The polymorphism of the gene encoding methylenetetrahydrofolate reductase (MTHFR) and folic acid nutritional status play important roles in atherosclerosis. The present study investigated the total homocysteine-lowering effect of folic acid in response to the MTHFR genotype in patients who have cardiovascular disease. METHODS: Twenty-three patients who had cardiovascular disease (ages 44 to 88 y) were supplemented with 5 mg of folic acid/d for 8 wk. Blood samples were collected before and after supplementation for the measurement of folic acid. The presence of the 677C-->T mutation was assessed by polymerase chain reaction followed by restriction enzyme analysis. RESULTS: After the 8 wk of folic acid supplementation, plasma total homocysteine decreased 40% in patients who had the TT genotype, 23% in those who had the CT genotype, 10% in those who had the CC genotype, and 27% in carriers of the T allele. The plasma total homocysteine-lowering effect of folic acid was significant only in patients who had the CT genotype and in carriers of the T allele. CONCLUSIONS: The MTHFR polymorphism may be involved in the total homocysteine-lowering effect of folic acid in patients who have cardiovascular disease. SN - 0899-9007 UR - https://www.unboundmedicine.com/medline/citation/15561486/Methylenetetrahydrofolate_reductase_polymorphism_determines_the_plasma_homocysteine_lowering_effect_of_large_dose_folic_acid_supplementation_in_patients_with_cardiovascular_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0899-9007(04)00187-X DB - PRIME DP - Unbound Medicine ER -